# A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

> **NCT01351103** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 185 (actual)

## Conditions studied

- Pancreatic Cancer
- BRAF Mutant Colorectal Cancer
- Melanoma
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Cancer
- Cervical Squamous Cell Cancer
- Esophageal Squamous Cell Cancer
- Lung Squamous Cell Cancer

## Interventions

- **DRUG:** LGK974
- **BIOLOGICAL:** PDR001

## Key facts

- **NCT ID:** NCT01351103
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2024-06-17
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351103, "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01351103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*